Skip Content
Page Banner Image

In the Know – March 2018

Volume 13, Issue 3



HD500 for Huntington’s Disease Rides Into its Fifth Year
Selkirk Record – March 1, 2018

After Angel Fredericks’ mother was diagnosed with Huntington’s disease, the Huntington Society of Manitoba became like a  beacon of hope for her and her family.  Click here to read the full article on page 10.

Stop, Drop and Plank 4 HD Challenge
HSC Blog – March 14, 2018

Have you heard of the latest HD social media challenge? Have you been nominated to participate? #StopDropandPlank4HD is the challenge that is taking the internet by a storm where participants do just like it sounds – stop, drop and plank for HD! When, where and how the plank is preformed is up to you. Click here to read the full story.

Ranch Retrievers: Robert’s Diamond in the Ruff
HSC Blog – March 8, 2018

Robert Deluca has had a long journey with Huntington disease (HD) since being diagnosed four years ago. Robert stays at home with his wife, Tati. The time has come, though, for Tati to return to work. Feeling nervous about being alone at home and having received recommendations from his neurologist, family doctor and HSC social worker to get an emotional support animal, Robert and Tati decided they needed to seek a companion for him. And who do they say is a man’s best friend? A dog, of course! Click here to read the full story.

Champion of Hope

Becoming a Champion of Hope monthly donor is simple and risk free. Click here to learn more about how a steady monthly contribution from you can help aid HD research, services and education.


CHDI Conference: Updates from Bev Heim-Myers, CEO
HSC Blog

The CHDI Scientific Conference always provides the opportunity to connect with our global scientific experts. Last evening was the opening of the conference and it was wonderful to see Dr. Jeff Carroll, Dr. Ed Wild, Dr. Mark Guttman, Dr. Marcy McDonald, Dr. Jim Gusuella, Dr. Blair Leavitt, Dr. Lynn Raymond and many others (365 attendees in total).

Click here to read Bev’s full summary of day one.

Click here to read Bev’s full summary of days two and three.

Huntington’s Disease Therapeutics Conference 2018

Jeff and Ed report from the Huntington’s Disease Therapeutics Conference – the biggest annual gathering of HD researchers. This year’s conference is bigger and more exciting than ever.

Click here to read their full summary of day one.

Click here to read their full summary of day two.

Click here to read their full summary of day three.


IONIS-HTTRx (RG6042) Program Update
HSC Blog – March 1, 2018

Today Ionis released positive top-line data from their completed Phase 1/2 study of IONIS-HTTRx in people with early stage Huntington disease at the 13th Annual CHDI HD conference. The data demonstrates that the IONIS-HTTRx drug has successfully lowered the harmful huntingtin protein in cerebral spinal fluid, the drug is safe and well tolerated. This data is promising and gives us substantive hope that a treatment is near. Click here for the full breakdown on our website.

Roche, Ionis herald a big win in early-stage Huntington’s disease trial, demonstrate disease modifying potential
EndPoints News – March 1, 2018

Ionis and its partners at Roche have unveiled the biomarker data from a Phase I/II study that recently drove the pharma giant to follow through with a $45 million payment to option rights to IONIS-HTT Rx (RG6042). Click here to read the full article.

IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington’s Disease
GlobeAdvisor – March 1, 2018

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), a leader in antisense therapeutics, today announced the presentation of positive top-line data from a completed Phase 1/2 study of IONIS-HTTRx (RG6042) in people with early stage Huntington’s disease (HD) at the 13th Annual CHDI HD conference. Click here to read the full article.

Teva and Intel are Using a Wearable to Track Huntington’s Disease Symptoms
InfoTime – March 7, 2018

In more good news about wearables making a difference, Israeli pharmaceutical firm Teva has partnered with Intel to use a smartwatch to monitor Huntington’s Disease in order to gather more data for treatment. Click here to read the full article.

Cancer ‘Super Assassin’: Huntington’s Disease Molecule Can Target and Kill All Tumor Cells, Scientists Find
Newsweek – February 12, 2018

Scientists have destroyed numerous types of human cancer cells with a toxic molecule characteristic of fatal genetic illness Huntington’s disease. The researchers hailed the molecule—which has killed both human and mouse ovarian, breast, prostate, liver, brain, lung, skin and colon cancer cell lines in mice—as a “super assassin.” Click here to read the full article.

Huntington’s Disease Provides New Cancer Weapon
Science Daily – February 12, 2018

Patients with Huntington’s disease, a fatal genetic illness that causes the breakdown of nerve cells in the brain, have up to 80 percent less cancer than the general population. Northwestern Medicine scientists have discovered why Huntington’s is so toxic to cancer cells and harnessed it for a novel approach to treat cancer, a new study reports. Click here to read the full article.



We support those facing huntington disease
 Latest Blog


Let Us Know How We Can Help
Enter your name, email address and question(s) below for assistance.



Stay in Touch!
Enter your email address below to receive occasional updates.

Newsletter Sign-up